PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome

Neuro-Oncology

Volumn 14, Issue 9, 2012, Pages 1146-1152

  Mueller, Sabine ^a   Phillips, Joanna ^b   Onar Thomas, Arzu ^c   Romero, Eloy ^a   Zheng, Shichun ^a   Wiencke, John K ^a   McBride, Sean M ^d   Cowdrey, Cynthia ^a   Prados, Michael D ^a   Weiss, William A ^a   Berger, Mitchel S ^a   Gupta, Nalin ^a   Haas Kogan, Daphne A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

Author keywords

Pediatric gliomas; PI3K Akt mTOR; PTEN promoter methylation

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN S6;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA METHYLATION; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; SCHOOL CHILD; SIGNAL TRANSDUCTION;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; INFANT, NEWBORN; MALE; NEOPLASM GRADING; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84867505054     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos140     Document Type: Article

References (23)

1. Schiffman JD, Hodgson JG, Van Den Berg SR, et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 2010;70:512-519.
2. Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28:3061-3068.
3. Horbinski C, Hamilton RL, Nikiforov Y, Pollack IF. Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol. 2011;119:641-649.
4. Hawkins CE, Walker E, Mohamed N, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low grade astrocytoma. Clin Cancer Res. 2011;17:4790-8.
5. Choe G, Horvath S, Cloughesy TF, et al. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003;63:2742-2746.
6. Ermoian RP, Furniss CS, Lamborn KR, et al. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res. 2002;8:1100-1106.
7. Rasheed BK, Stenzel TT, McLendon RE, et al. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 1997;57:4187-4190.
8. Wiencke JK, Zheng S, Jelluma N, et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol. 2007;9:271-279.
9. McBride SM, Perez DA, Polley MY, et al. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol. 2010;97:33-40.
10. Qaddoumi I, Sultan I, Gajjar A. Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database. Cancer. 2009;115:5761-5770.
11. Finlay JL, Boyett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol. 1995;13:112-123.
12. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer. 1994;74:1784-1791.
13. Janny P, Cure H, Mohr M, et al. Low grade supratentorial astrocytomas. Management and prognostic factors. Cancer. 1994;73:1937-1945.
14. Sposto R, Ertel IJ, Jenkin RD, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol. 1989;7:165-177.
15. Song KS, Phi JH, Cho BK, et al. Long-term outcomes in children with glioblastoma. J Neurosurg Pediatr. 2010;6:145-149.
16. Stokland T, Liu JF, Ironside JW, et al. Amultivariate analysis of factors determining tumor progression in childhood low-grade glioma: a populationbased cohort study (CCLG CNS9702). Neuro Oncol. 2010;12:1257-1268.
17. Bredel M, Pollack IF, Hamilton RL, James CD. Epidermal growth factor receptor expression and gene amplification in high-grade nonbrainstem gliomas of childhood. Clin Cancer Res. 1999;5:1786-1792.
18. Pollack IF, Hamilton RL, James CD, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg. 2006;105:418-424.
19. Thorarinsdottir HK, Santi M, McCarter R, et al. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas. Clin Cancer Res. 2008;14:3386-3394.
20. Pollack IF, Hamilton RL, Burger PC, et al. Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group. J Neurooncol. 2010;99:155-163.
21. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445-1453.
22. Gera JF, Mellinghoff IK, Shi Y, et al. Akt activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2004;279:2737-2746.
23. Noh WC, Mondesire WH, Peng J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res. 2004;10:1013-1023.